United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Purchases New Position in Bristol Myers Squibb Company $BMY

Key Points

• United Super Pty Ltd opened a new position in Bristol Myers Squibb during the fourth quarter, buying 959,809 shares valued at about $51.8 million.
• Institutional ownership remains high, with a number of large funds recently adding to their BMY stakes and 76.41% of the stock now held by institutional investors.
• Bristol Myers Squibb reported quarterly EPS of $1.58 and revenue of $11.49 billion, both beating estimates, while the company also pays a 4.4% dividend yield on its $0.63 quarterly payout.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 959,809 shares of the biopharmaceutical company's stock, valued at approximately $51,772,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Geode Capital Management LLC boosted its stake in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock valued at $2,837,026,000 after buying an additional 6,084,046 shares during the last quarter. Man Group plc boosted its stake in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock valued at $345,594,000 after buying an additional 5,503,391 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of Bristol Myers Squibb by 530.6% in the 3rd quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company's stock valued at $245,946,000 after acquiring an additional 4,588,601 shares during the last quarter. Van ECK Associates Corp lifted its holdings in shares of Bristol Myers Squibb by 67.8% in the 3rd quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company's stock valued at $444,682,000 after acquiring an additional 3,982,439 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Bristol Myers Squibb by 31.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company's stock valued at $669,012,000 after acquiring an additional 3,522,696 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on BMY. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Morgan Stanley reaffirmed an "underweight" rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a report on Friday, February 6th. Bank of America lowered their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a report on Thursday, April 9th. Guggenheim reaffirmed a "buy" rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Sunday, April 19th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $61.31.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.05% of the company's stock.

Bristol Myers Squibb Stock Down 1.0%

Shares of NYSE BMY opened at $56.93 on Friday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The company has a market cap of $116.26 billion, a P/E ratio of 15.99, a PEG ratio of 0.16 and a beta of 0.26. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm has a 50-day simple moving average of $58.36 and a two-hundred day simple moving average of $56.25.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.4%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.